Skip to content

FEBELCO

Active
Cooperative companyfounded 1996active for 30 yearsEigenlostraat 1, 9100 Sint-Niklaas, BelgiumKBO/BCE: BE 0458.780.306
Summary

FEBELCO has been active since 1996 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €103.6m and a net result of €4.4m. Equity is shrinking by about 5.5% per year across the filed financial years. Its solvency ranks better than 30% of 6,105 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
Largest employer in East Flanders, Wholesale trade sector8 sites
Size
€1.79bnturnover 2025
Staff
948.1 FTE
Equity
€103.6m
Profit
€4.4m
Standalone figures, without subsidiaries
Financial health
80 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.5%
Structure
Parent
PHARMACIE BIA · 100%
Holdings
6
  • KST PharmaManaging director · permanent representative Koen Straetmans
Auditor: Moore AuditAccounts 72 days early3 of 30 deeds read
Why 80raises riskLiquidity: current ratio 1.19, cash €226,3398 establishment unitslowers riskFounded in 1996Size: turnover €1.79bn, 948.1 FTE, total assets €381.9m, files consolidated accountsShow the evidence

Checked score

Score 2025
80 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 37% of its sector peers (NACE 46, large)
Financial strength · tick = 2024
Weak
Solvency 52-5
equity 27.1% of total assets
Liquidity 17-3
short-term debt 62.6% · cash 0.1%
Profitability 55+2
return on assets 1.2%
Bankruptcy probability, 12 months
0.5% Very low
0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (132 companies, NACE 46, large)
Last 24 months 11-2024: 0.5% 12-2024: 0.5%● unchanged vs 11-2024 01-2025: 0.5%● unchanged vs 12-2024 02-2025: 0.5%● unchanged vs 01-2025lowest value 03-2025: 0.5%● unchanged vs 02-2025 04-2025: 0.5%● unchanged vs 03-2025 05-2025: 0.5%● unchanged vs 04-2025 06-2025: 0.5%● unchanged vs 05-2025highest value 07-2025: 0.5%● unchanged vs 06-2025 08-2025: 0.5%● unchanged vs 07-2025 09-2025: 0.5%● unchanged vs 08-2025 10-2025: 0.5%● unchanged vs 09-2025 11-2025: 0.5%● unchanged vs 10-2025 12-2025: 0.5%● unchanged vs 11-2025 01-2026: 0.5%● unchanged vs 12-2025 02-2026: 0.5%● unchanged vs 01-2026 03-2026: 0.5%● unchanged vs 02-2026 04-2026: 0.5%● unchanged vs 03-2026 05-2026: 0.5%● unchanged vs 04-2026 06-2026: 0.5%● unchanged vs 05-2026 07-2026: 0.5%● unchanged vs 06-2026 08-2026: 0.5%● unchanged vs 07-2026 09-2026: 0.5%● unchanged vs 08-2026 10-2026: 0.5%● unchanged vs 09-2026
Credit of up to €8,250,000 on 30-day terms is acceptable
Liquidity tight (current ratio 1.19, compared with 1.2 in 2024, below the usual 1.5; short-term debt: 62.6% and cash: 0.1% of total assets), and 72.9% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, large): better than 37% on solvency, 25% on liquidity, 42% on profitability and 44% on growth.

The bankruptcy probability was computed on 18-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 1.19, cash €226,339
NBB · annual accounts
lowers risk · Founded in 1996
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Size: turnover €1.79bn, 948.1 FTE, total assets €381.9m, files consolidated accounts
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · 8 establishment units
KBO · seat and establishments
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 20-05-2026, 72 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
72 days early
2024
44 days early
2023
27 days early
2022
49 days early
2021
34 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 5 accounts on average 45 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 17 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
18-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Resignations: BV ALEXO, Johan Lamoot and…Permanent representatives: Olivier Delaere, Koen…
  2. Annual accounts filedfinancial year 2025 · full…
  3. Annual accounts filedfinancial year 2025 · consolidated

Key points

  • Caution: Board changedlatest change 18-05-2026 · 1 in office 1 joined · 3 left View
  • Positive: Largest employer in East Flanders, Wholesale trade sectorin the Checked rankings No. 1 View
  • Positive: 7 years of growth in a rowturnover 2025: €1.79bn 7 years View
  • Controlled by PHARMACIE BIAthe company in turn controls 38 companies 100% View
  • Flemish supportawarded from 2022 to 2025 €355,851 View
  • Positive: Always filed on timeaccounts within the deadline every year 5 years View

By topic

Financials

Financial year
2025
Turnover
€1.79bn
Profit
€4.4m
Solvency
27.1%
Turnover▲ 4.2%
Net result
20182025
Go to Financials

Board & ownership

Board
1 member
Parent
PHARMACIE BIA · 100%
Auditor
Moore Audit
  • KST PharmaManaging director
Go to Board & ownership

Timeline

Events
57
Since
1998
Next accounts
by 31-07-2027
  1. 06-10-2025Permanent representative: Olivier Delaere
  2. 17-06-2025Annual accounts filed
  3. 17-06-2025Annual accounts filed
Go to Timeline

Company details

Sites
8
Legal form
Cooperative company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
11-09-1996
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.